BNP Paribas Financial Markets Acquires 22,785 Shares of Catalent, Inc. (NYSE:CTLT)

BNP Paribas Financial Markets grew its position in Catalent, Inc. (NYSE:CTLT - Free Report) by 9.3% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 267,219 shares of the company's stock after purchasing an additional 22,785 shares during the period. BNP Paribas Financial Markets owned about 0.15% of Catalent worth $16,185,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Brooklyn Investment Group acquired a new position in Catalent during the 3rd quarter worth about $31,000. Quantbot Technologies LP acquired a new position in Catalent during the 3rd quarter worth about $7,222,000. FMR LLC lifted its position in Catalent by 4.8% during the 3rd quarter. FMR LLC now owns 265,369 shares of the company's stock worth $16,073,000 after buying an additional 12,241 shares in the last quarter. Bank of Montreal Can lifted its position in Catalent by 181.5% during the 3rd quarter. Bank of Montreal Can now owns 1,813,167 shares of the company's stock worth $109,388,000 after buying an additional 1,169,044 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Catalent during the 3rd quarter worth about $1,131,000.

Insider Buying and Selling

In related news, Director Michelle R. Ryan sold 2,800 shares of the company's stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the sale, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. This represents a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider David Mcerlane sold 1,994 shares of the company's stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now owns 36,304 shares of the company's stock, valued at $2,177,150.88. This trade represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,114 shares of company stock valued at $305,931 over the last ninety days. 0.31% of the stock is owned by company insiders.

Catalent Price Performance

Shares of NYSE CTLT traded up $0.11 during mid-day trading on Friday, reaching $61.11. The company had a trading volume of 771,192 shares, compared to its average volume of 1,870,216. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. Catalent, Inc. has a one year low of $36.74 and a one year high of $61.50. The business's 50-day simple moving average is $59.90 and its 200 day simple moving average is $58.49.

Catalent (NYSE:CTLT - Get Free Report) last released its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the prior year, the firm earned ($0.10) EPS. The business's revenue was up 4.2% on a year-over-year basis. As a group, sell-side analysts forecast that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. StockNews.com downgraded shares of Catalent from a "hold" rating to a "sell" rating in a research report on Friday, November 22nd. Robert W. Baird restated a "neutral" rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. Baird R W downgraded shares of Catalent from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 24th. Finally, William Blair reaffirmed a "market perform" rating on shares of Catalent in a research note on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $63.40.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.